Clinical trial · Interventional
Turmeric as Treatment in Epilepsy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Funding
Summary
Brief summary (as posted)
This is a single center open-label pilot clinical trial of patients 1-70 years of age with greater than 6 seizures per month diagnosed with Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis, or focal seizures. Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months. Patients and caregivers will be asked to keep a seizure diary logging all clinical events during the course of the study. Serum comprehensive metabolic panel, complete blood count with differential, and antiseizure medication levels, will be monitored at baseline, 1.5 months, and at the end of 3 months.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Dravet Syndrome | — | UNRESOLVED | — |
| Epilepsy | — | UNRESOLVED | — |
| Focal Seizures | — | UNRESOLVED | — |
| Lennox-Gastaut Syndrome | — | UNRESOLVED | — |
| Tuberous Sclerosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Turmeric | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Turmeric Oil
- description
- stable dose of orally administered turmeric oil
- interventionNames
- Dietary Supplement: Turmeric
Primary outcomes (1)
- measure
- Number of epilepsy patients enrolled in study
- timeFrame
- 3 months
- description
- feasibility of recruiting patients into a prospective study designed to evaluate the effect of orally ingested turmeric oil on seizures.
Secondary outcomes (1)
- measure
- Number of epilepsy seizures post epilepsy treatment with turmeric
- timeFrame
- 3 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with greater than greater than six seizures per month diagnosed with Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis, or focal seizures followed at NYU CEC. Exclusion Criteria: * Patients expected to have changes to any medications or supplements during study period * exposure to any investigational agent in the month prior to study entry * pregnant or breast feeding women, positive pregnancy test * history of non-compliance * known drug or alcohol dependence * known baseline hematologic * liver function * renal function * absorption * absorption
References
Publications (0)
Data not yet available